Press Room

13th DPI Symposium

Start
Thursday, November 24, 2022 - 09:00
Location: Toyama, Japan

 

Schedule your meeting today with Yasushi Usuda - Regional Sales Director
yasushi-usuda-photo
 

 

Let’s discuss your project together.

 

Eunice Costa, R&D Director – Inhalation and Advanced Drug Delivery, will be a speaker at the symposium.

 

  • Title: High Dosage DPI - Formulation and process development considerations
  • Abstract: The inhalation route of administration presents several advantages, and in the last years the drug loads administered to the lung have increased more than 10 times for drugs such as antibiotics and biopharmaceuticals. The increase in dose comes with manufacturing and delivery challenges for both small and large molecules - the generation of a stable aerosol able to reach the lungs while preserving the integrity of the active ingredient, rendering it safe and effective. In the presentation the in house strategies for the manufacturing and pulmonary delivery of high dosages will be explored, from particle engineering of crystalline fine particles to spray-dried formulations, coupled with Hovione devices. This presentation will showcase the most promising high dosage formulation strategies with focus on particle engineering methods for dry powder inhalation such as spray drying.

 

Schedule a meeting today!

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025